The company made this announcement during trading hours on Monday, 8 February 2010, when the stock had declined 2.40% to Rs 1513.25.
Meanwhile, the BSE Sensex was up 79.30 points, or 0.48% to 16,012.23.
On BSE, 34,900 shares were traded in the counter as against an average daily volume of 41,698 shares in the past one quarter.
The stock hit a high of Rs 1571.80 and a low of Rs 1512.10 so far during the day. The stock had hit a lifetime high of Rs 1624 on 2 February 2010 and a 52-week low of Rs 565 on 6 March 2009.
The large-cap stock had outperformed the market over the past one month till 8 February 2010, rising 5.15% as compared to the Sensex's 9.15% fall. It had also outperformed the market in the past one quarter, gaining 14.38% as compared to the Sensex's decline of 1.38%.
The company's equity capital is Rs 88.92 crore. Face value per share is Rs 10.
The current price of Rs 1568.15 discounts the company's Q3 December 2009 annualized EPS of Rs 100.23, by a PE multiple of 15.65.
The drug is the generic version of Novartis' Lotrel capsules and is used for treating hypertension. As per IMS Health sales data, the drug had an annual sale of approximately $1.1 billion for the 12 months period ended September 2009 in the US.
Lupin's net profit jumped 152.7% to Rs 222.70 crore on 37.8% increase in net sales to Rs 1004.50 crore in Q3 December 2009 over Q3 December 2008.
Lupin is engaged in manufacturing active pharmaceutical ingredients and formulations.
Promoters have pledged more than 44.72 lakh shares representing 5.03% of the equity capital of the company. The total promoter shareholding in the company is 47.18% (as on 31 December 2009).